anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Bcr-Abl1 kinase domain mutations are the most prevalent cause of treatment resistance in chronic myeloid leukaemia (CML). Alternate resistance pathways nevertheless exist, and cell line experiments show certain patterns in the gain, and loss, of some of these alternate adaptations. These adaptations have clinical consequences when the tumour develops mechanisms that are beneficial to its growth under treatment, but slow down its growth when not treated. The results of temporarily halting treatment in CML have not been widely discussed in the clinic and there is no robust theoretical model that could suggest when such a pause in therapy can be tolerated. We constructed a dynamic model of how mechanisms such as Bcr-Abl1 overexpression and drug transporter upregulation evolve to produce resistance in cell lines, and investigate its behaviour subject to different treatment schedules, in particular when the treatment is paused ('drug holiday'). Our study results suggest that the presence of additional resistance mechanisms creates an environment which favours mutations that are either preexisting or occur late during treatment. Importantly, the results suggest the existence of tumour drug addiction, where cancer cells become dependent on the drug for (optimal) survival, which could be exploited through a treatment holiday. All simulation code is available at https://github.com/Sandalmoth/dual-adaptation.
Infants in the group receive CPAP for respiratory support in the delivery room. In addition, they receive a total of 15 sustained lung inflations in the first 96 hours of life; 6 in the first day, 3 in the second day, 3 in the third day and 3 in the forth day of life.
The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-Kα radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2θ, and the X-ray powder diffraction pattern is shown in FIG.  1 . The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.
This viewpoint article, which represents the opinions of the authors, discusses the barriers to developing a patient-oriented frailty website and potential solutions. A patient-oriented frailty website is a health resource where community-dwelling older adults can navigate to and answer a series of health-related questions to receive a frailty score and health summary. This information could then be shared with health care professionals to help with the understanding of health status prior to acute illness, as well as to screen and identify older adult individuals for frailty. Our viewpoints were drawn from 2 discussion sessions that included caregivers and care providers, as well as community-dwelling older adults. We found that barriers to a patient-oriented frailty website include, but are not limited to, its inherent restrictiveness to frail persons, concerns over data privacy, time commitment worries, and the need for health and lifestyle resources in addition to an assessment summary. For each barrier, we discuss potential solutions and caveats to those solutions, including assistance from caregivers, hosting the website on a trusted source, reducing the number of health questions that need to be answered, and providing resources tailored to each users' responses, respectively. In addition to screening and identifying frail older adults, a patient-oriented frailty website will help promote healthy aging in nonfrail adults, encourage aging in place, support real-time monitoring, and enable personalized and preventative care.
Generation of polyethylene wear debris and peri‑prosthetic bone resorption have been identified as potential causes of acetabular component loosening in Total Hip Arthroplasty. This study was aimed at optimization of a functionally graded porous acetabular component to minimize peri‑prosthetic bone resorption and polyethylene liner wear. Porosity levels (porosity values at acetabular rim, and dome) and functional gradation exponents (radial and polar) were considered as the design parameters. The relationship between porosity and elastic properties were obtained from numerical homogenization. The multi-objective optimization was carried out using a non-dominated sorting genetic algorithm integrated with finite element analysis of the hemipelvises subject to various loading conditions of common daily activities. The optimal functionally graded porous designs (OFGPs -1, -2, -3, -4, -5) exhibited less strain-shielding in cancellous bone compared to solid metal-backing. Maximum bone-implant interfacial micromotions (63-68 μm) for OFGPs were found to be close to that of solid metal-backing (66 μm), which might facilitate bone ingrowth. However, OFGPs exhibited an increase in volumetric wear (3-10 %) compared to solid metal-backing. The objective functions were found to be more sensitive to changes in polar gradation exponent than radial gradation exponent, based on the Sobol' method. Considering the common failure mechanisms, OFGP-1, having highly porous acetabular rim and less porous dome, appears to be a better alternative to the solid metal-backing.
Chronic tinnitus is a common symptom of the auditory system. A causal therapy does not yet exist. The recommended treatment includes expert counseling, psychotherapeutic interventions, particularly cognitive behavioral therapy, and measures to improve hearing. The treatment modules are multimodal and can be combined individually. Depending on the severity of the different disease dimensions (tinnitus and comorbidities), a rehabilitative approach may be useful for maintaining health and occupational ability. In addition to a thorough and well-founded diagnosis and counseling, specific cognitive behavioral therapy and non-specific psychotherapeutic interventions (mindfulness/relaxation) on an individual or group basis, physiotherapy, and exercise, as well as auditory rehabilitation measures (hearing aids, auditory therapy) in the context of multimodal therapy approaches are necessary.
The main objective of this project is to assess the impact of a plyometric program on power, speed, agility, reactive strength index and stiffness in male athletes of different levels of maturation. The study takes the form of a short-term experiment (12 weeks), involving 30 young athletes with a minimum of two years of experience in systematic sports training. Participants are divided into an experimental group and a control group. The experimental group undergoes a 12-week plyometric training program, implemented twice a week within training sessions immediately following warm-ups. The control group engages in technical-tactical exercises. The program is developed by the authors of the research project based on current knowledge and requirements for creating an effective and safe plyometric program. Randomization is performed using a computer random generator. Participants undergo two testing sessions: one prior to the training intervention and the other one week after its completion. Age, height, weight, and body composition are measured using a personal scale with an integrated stadiometer. Tests include a 30-m sprint, countermovement jump, broad jump, unilateral triple jump, drop jump (reactive strength index), 20 submaximal vertical jumps (lower limb stiffness), BlazePod reaction test, and 505 agility test. The maturity status of the participants is evaluated using the Mirwald method and is used as a covariate in the subsequent statistical analysis. Findings of this research may provide crucial insights for targeted integration of plyometric methods during the developmental and maturation phases of young athletes.
Subjects will receive a therapy based on Tumor-infiltrating Lymphocyte (NEXTGEN-TIL product) preceded by a preparative non-myeloablative lymphodepleting (NMA-DL) regimen and followed by IL-2 infusion. Patients will be followed-up for 2 years, assessed at weeks 2, 3, 4, 6, 9, 12, 18, 24, 30, 36 (9 months), and then at 1 year, 1,5 and 2 years.
After consenting to participate, participants will be asked to complete a pre-experience questionnaire. The investigators will ask participants questions to evaluate their general and current state of stress as well as gather some baseline health information. Although the questionnaires ask questions about anxiety, they are being conducted for research purposes, so if participants are feeling anxious they should discuss this with their primary care provider or other doctor. The investigators think it should take about 5 minutes to complete the pre-experience questionnaire. If participants feel uncomfortable or embarrassed answering any question, they may skip it. The questionnaire will not contain any information that could be used to identify participants. If participants do not feel comfortable answering surveys then this would result in withdrawal from the study. Participants would be politely notified of your withdrawal and not complete the study.

Participants will then place the VR headset over their head along with over the ear headphones. The research member will ensure safety and comfort then instruct participant how to begin the experience through the headset. The experience includes relaxing images, shapes, and colors that change and evolve slowly. These visuals are also paired with music, which can be adjusted at the start of the experience with the assistance of the researcher (participant will not have to control sound or light). Participants will not have a choice as to the content viewed during this experience. If at any time during the experience participant would like to stop, you may feel free to signal to the researcher, ask to stop, or just remove the headset and headphones.

After completion of the experience, participants will be asked to complete a post-experience survey. Investigators think this should take about 5 minutes to complete. Investigators will again ask about stress levels. Investigators will also gather feedback from participant about thoughts and attitudes towards the VR experience for stress reduction and potential usefulness in cardiac rehabilitation.

Physiological measures will be collected and monitored as follows: The heart rate and heart rate variability will be monitored via the PolarH10 heart rate monitor and chest strap and transmitted to the safely encrypted computer/tablet. There will be no info transmitted with the data aside from the time/date of the collecting. This will be a continuous recording from 5 minutes after you sit down to complete the survey until 5 minutes after the experience. The blood pressure cuff will be used 3 times: 5 minutes after you sit down but prior to the experience, at 15 minutes during the experience, and at the end of the experience. Respiratory rate will be observed by the researcher while you enter the survey data, and every 10 minutes during the experience, then as you complete the post-survey for a total of 5 measurements. The galvanic skin response (sweat gland activity) sensor will be placed at the same time as the heart rate monitor and will provide continuous monitoring for 5 minutes prior to the start of the experience and 5 minutes post-experience.
Healthcare systems face multiple challenges arising from demographic factors (population aging) and epidemiological factors (rise of chronic diseases and patients with multimorbidity) as well as threats to their financial sustainability when maintaining equitable access to medical and technological advances. Current healthcare models, based on specialized medical care, lead to fragmented care that can be harmful to the patient and is inefficient for the system due to the overuse of redundant, low-value medical acts. Internal medicine is the hospital-centered general medical specialty par excellence, providing a comprehensive and holistic vision that is centered on the patient and not on the disease. Internists should be the leading physicians in the hospital setting for complex patients with or those with an uncertain diagnosis. Internists must play a key role, as hospitalists do, in the continued care of acute patients hospitalized for medical or surgical diseases, establishing shared care models in multidisciplinary teams. Likewise, to guarantee continuity of care for chronic patients, internists must establish mechanisms for collaboration with primary care and nursing, participating in the development of new out-of-hospital care models that use the available technological resources. Internal medicine should play a leading role in graduate and postgraduate medical education to promote a holistic vision among medical students and residents in medical subspecialties.
PURPOSE:To obtain a 5-fluorouracil carrier having excellent antitumor activity and low toxicity, by reacting chitosan with chloroacetic acid and acetic anhydride and then reacting the obtd. compd. with 5-fluorouracil and triethylamine. CONSTITUTION:A chitosan deriv. of formula II (wherein m is 1-2; n is 1-2) is prepd. by reacting chitosan of formula I (wherein r is 100 or larger) with chloroacetic acid and acetic anhydride. Then, a 5-fluorouracil carrier of formula IV wherein 5-fluorouracil is bound by an amide bond and an ester bond through a lower alkylene group to the 2- and 6-positions of chitosan is obtd. by reacting the chitosan deriv. of formula II with 5-fluorouracil of formula III and triethylamine. This carrier is incorporated into tumor cells as it is and releases in the cells 5-fluorouracil which exhibits antitumor activity, and chitosan which is the carrier is decomposed and absorbed.
An implantable medical device is provided. The implantable medical device includes a core having an antisense oligonucleotide (ASO) dispersed within a core polymer matrix. The core polymer matrix includes an ethylene vinyl acetate copolymer. The ASO includes one or more nucleosides attached via internucleoside linkages. At least 10% of the internucleoside linkages comprise chemically modified internucleoside linkages. The implantable device is capable of releasing about 5% to about 60% of the ASO after a time period of about seven days.
The invention discloses a traditional Chinese medicine for treating perennial rhinitis. The traditional Chinese medicine is prepared from roots of small diuranthera, flowers of narrowleaf scabious, herb of annual fleabane, roots of delavay dobinea, flower-bud of rice paperplant, roots or stems of common epipremnum, wing nut barks, stems and leaves of ammopiptanthus, roots of scabrous elephantfoot, pear peel, water chestnuts, flowers and leaves of eritrichium pectinatum (Pall.) DC. var. rupestre (Pall.) brand., indochinese cassia fruits, willow herbs, wild jujube thorns, leaves of carambola, Chinese mahonia stems, radix schefflera octophyyla (Lour.) harms, herb of russian fenugreek and bark of tangut barberry. The pure natural Chinese herbs are adopted as raw materials, the traditional Chinese medicine treats both symptoms and root causes, is definite in curative effect and has no toxic or side effect, and relapse does not occur easily.
Fibrin-binding molecules are provided which include at least one peptide essentially corresponding to one or both of the following portions of the natural fibronectin molecule. The first portion is that portion which includes the  4  F1. 5  F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the N-terminal 25.9 kDa proteolytic fragment. The second portion includes the  10  F1. 11  F1 module pair of fibronectin and includes no more of the natural fibronectin molecule than the C-terminal 11 kDa proteolytic fragment. Also disclosed are nucleic acid molecules encoding the fibrin-binding peptides, methods for making the peptides, methods for using the peptides in the diagnosis and treatment of cardiovascular, peripheral vascular, cerebrovascular, and other conditions associated with fibrin deposition, and assay methods for detecting a fibrin-binding molecule and for measuring fibrin.
Methods, apparatus, systems, and computer program products for providing patient predictions are provided in various embodiments. Responsive to receiving an indication of initiation of a patient interaction, a model for the patient is initiated by an assessment computing entity. The model has been trained using machine learning and the model is configured to generate a prediction for the patient. The prediction comprises at least one of an acuity score or a mortality prediction. Responsive to identifying a prediction trigger, the assessment computing entity updates the model for the patient based at least in part on medical data corresponding to the patient. The assessment computing entity generates the prediction using the updated model. The assessment computing entity provides at least a portion of the prediction such that the at least a portion of the prediction may be used to update an electronic health record corresponding to the patient and/or provided to a clinician for review.
Skin grafting is the mainstay treatment in burn patients. However, in the scenario of soft tissue deficit along with exposure of critical structures, free flap is the only reconstructive option to provide adequate coverage. The aim of the study is to review indications and surgical outcomes of burn patients requiring free tissue transfer. A retrospective cohort study was conducted to review all patients who underwent free tissue transfer for burn-related injuries between March 2012 and June 2023. A total of 13 patients required a free flap for their reconstruction. Eleven flaps were performed during the acute care and 2 were performed for delayed reconstruction. Patients were 69% males and 31% females, with a mean age of 45.5 ± 16 years and a mean BMI of 25.4 ± 6.5. The mean follow-up was 13.5 ± 13.9 months. Indications for free tissue transfer were bone exposure (92%) and severe neck burn contracture (8%). Overall complications rate was 54%. Complications included free flap loss (15%), hematoma (15%), vein thrombosis of the anastomosis (15%), infection (8%), amputation (8%), and wound healing issues (23%). Overall, 38% of the patients required re-operations including venous anastomosis revision, hematoma evacuation, debridement, skin grafting, and debulking. Although sometimes free flap remains the only reconstructive option in severe burn-related injuries, it is only rarely used. However, they carry a high risk of complications and should be considered only as the last resort for limb or life-threatening situations.
Sotalol Hydrochloride Syrup 5 mg/mL can be compounded using Simple Syrup containing 0.1% sodium benzoate (Syrup, NF) as follows:

  1. Measure 120 mL of Simple Syrup.   

  2. Transfer the syrup to a 6-ounce amber plastic (polyethylene terephthalate [PET]) prescription bottle. An oversized bottle is used to allow for a headspace, so that there will be more effective mixing during shaking of the bottle.   

  3. Add five (5) Sotalol Hydrochloride 120 mg tablets to the bottle. These tablets are added intact; it is not necessary to crush the tablets. The addition of the tablets can also be done first. The tablets can also be crushed if preferred. If the tablets are crushed, care should be taken to transfer the entire quantity of tablet powder into the bottle containing the syrup.   

  4. Shake the bottle to wet the entire surface of the tablets. If the tablets have been crushed, shake the bottle until the endpoint is achieved.   

  5. Allow the tablets to hydrate for at least two hours.   

  6. After at least two hours have elapsed, shake the bottle intermittently over the course of at least another two hours until the tablets are completely disintegrated. The tablets can be allowed to hydrate overnight to simplify the disintegration process.



The endpoint is achieved when a dispersion of fine particles in the syrup is obtained.

This compounding procedure results in a solution containing 5 mg/mL of sotalol HCl. The fine solid particles are the water-insoluble inactive ingredients of the tablets.

Stability studies indicate that the suspension is stable for three months when stored at 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature] and ambient humidity.
People with an evening chronotype have an increased risk of experiencing a major depressive disorder (MDD). It is unclear if this effect is predominantly related to the initial development of MDD or also present in recurrent episodes. The current study aimed to investigate if the association between chronotype and depressive severity in MDD patients is comparable in MDD patients with first and recurrent episodes. 386 MDD patients, 70.7% females and aged between 16 and 64, participated in the study. The Morningness - Eveningness Questionnaire (MEQ), Pittsburgh Sleep Quality Index (PSQI), Multidimensional Fatigue Inventory (MFI20), and Quick Inventory of Depressive Symptomatology (QIDS-SR16) were administered to participants to determine chronotype, sleep quality, fatigue level, and depressive severity, respectively. Multivariate regression models were utilized to analyze how chronotype influences depressive severity. The study showed that chronotype, sleep quality, and fatigue level were all associated with depressive severity. Eveningness significantly predicted an increase in depressive severity independently of sleep quality and fatigue level only in patients with the first episode (-0.068, p = 0.010), but not in patients with recurrent episodes (0.013, p = 0.594). Circadian-focused treatment should be considered in first-episode depression only.
Immediately after hepatectomy, 1 mg terlipressin was given intravenously after hemostasis was achieved. After surgery, participants were routinely managed, and terlipressin were administrated at a dosage of 2 mg per day for 4 days.
PURPOSE:To obtain a composition for oral cavity application in which astringent feeling characteristic to a polyphosphate is removed by the synergic effect of the polyphosphate and an alkali metal sulfate and which has excellent aftertaste by compounding a polyphosphoric acid with the alkali metal sulfate. CONSTITUTION:This composition for oral cavity application is obtained by compounding a polyphosphoric acid with an alkali metal sulfate (e.g. sodium sulfate and potassium sulfate). By compounding the composition with a glycyrrhizinate, greater improving effect against the astringent feeling is obtained. As the polyphosphoric acid, a compound expressed by formula I [M is Na; (k) and (n) each is more than 1] (e.g. sodium pyrophosphate and sodium tripolyphosphate), a compound of formula II [(m)>=3] (e.g. sodium trimetaphosphate and potassium tetrametaphosphate), etc., each of which is water soluble, is preferably used. As the glycyrrhizinate, disodium glycyrrhizinate, dipotassium glycyrrhizinate, monoammonium glycyrrhizinate, etc., is preferably used.